Description

Pradaxa (dabigatran etexilate) capsules 110 mg. №60

Ingredients

Active ingredient: Dabigatran etexilate mesylate. Inactive ingredients may include acacia, hypromellose, talc, and others.

Dosage

Recommended dosage: The usual dose is 220 mg once daily. For patients with renal impairment, dosage adjustments may be necessary.

Indications

Pradaxa is indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

Contraindications

Do not use Pradaxa if you have artificial heart valves or if you have a history of bleeding disorders.

Directions

Take Pradaxa exactly as prescribed by your healthcare provider. Do not stop taking the medication without consulting your doctor.

Scientific Evidence

Pradaxa (dabigatran etexilate) has been extensively studied in clinical trials. Research has shown that Pradaxa is non-inferior to warfarin in preventing stroke and systemic embolism in patients with atrial fibrillation. The RE-LY trial demonstrated the efficacy and safety of Pradaxa compared to warfarin, with a lower risk of major bleeding events.

Additional Information

Pradaxa works by inhibiting thrombin, a key enzyme in the coagulation cascade. Unlike warfarin, Pradaxa does not require routine monitoring of blood levels. It has a rapid onset of action and a predictable anticoagulant effect. Pradaxa has a half-life of about 12-17 hours, allowing for once-daily dosing.

Pradaxa has shown to have a more predictable anticoagulant effect and fewer drug interactions compared to warfarin. It has become a preferred choice for stroke prevention in patients with atrial fibrillation due to its convenience and efficacy.

• Pradaxa is a direct thrombin inhibitor.
• It offers a more predictable anticoagulant effect compared to warfarin.
• Pradaxa has a rapid onset of action and does not require routine blood monitoring.